Autolus Therapeutics (AUTL) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Zura Bio (ZURA) over the past year, gaining 2.8% versus a loss of 11.3%. Autolus Therapeutics is the larger company by market cap ($481.8 million vs $383.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | ZURA |
|---|---|---|
| Share price | $1.81 | $4.00 |
| Market cap | $481.75M | $383.32M |
| 1-day change | +2.26% | -3.15% |
| YTD return | -9.05% | -23.66% |
| 1-year return | +2.84% | -11.31% |
| 5-year return | -70.52% | — |
| EPS (TTM) | $-1.09 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $7.44 |
| 52-week low | $1.18 | $3.15 |
| Distance from 52-week high | -29.84% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +382.32% | +350.00% |
| Average volume | 2.10M | 1.44M |
| Shares outstanding | 266.16M | 95.83M |
| Employees | 752 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed ZURA by 14.1 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
AUTL vs ZURA FAQ
Which is bigger, Autolus Therapeutics or Zura Bio?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $481.75M compared with $383.32M for Zura Bio (ZURA).
Which stock has performed better over the past year, AUTL or ZURA?
AUTL returned +2.84% over the past 12 months, compared with -11.31% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.